• Full-year revenue of $11.1M up 29% on FY24
• Normalised Operating EBITDA* of $1.4M up 24% on FY24
• Record cash receipts from customers of $14.0M up 72% on FY24

Resonance Health Limited (ASX: RHT) reported its FY25 full-year results, highlighting strong financial performance across key metrics. Revenue increased by 29% to $11.1M, with a 3-year CAGR of 43% from FY23 to FY25. Normalised Operating EBITDA grew by 24% to $1.4M, and the company achieved record cash receipts from customers of $14.0M, up 72% on FY24. The company's business transformation into three profit-generating segments - Central Imaging (SaMD), Resonance Clinical (CRO), and Investigator Sites (TrialsWest) - is well underway, with all segments now positively contributing at an operating level. Key achievements include the completion of a major clinical trial contract, several new and extended SaMD service agreements, and the expansion of the TrialsWest network of investigator sites. The company also implemented a major cost efficiency program, expected to result in annual savings of approximately $1.1M going forward.

For FY26, Resonance Health expects revenue of $17M and Underlying EBITDA of $2M. The company is targeting EBITDA margins of around 25% over the coming periods as operational leverage drives margin expansion.

Resonance Health expects continued growth in its SaMD business, full-year impact from the second TrialsWest site and establishment of a third site, and further push to offer services across its three business segments to clinical trial customers. The company also has an acquisitive pipeline of potential business targets across the clinical trial ecosystem. Strong tailwinds from projected domestic and international clinical trials market growth are expected to drive strong FY26 performance.